Denali Therapeutics Inc. (DNLI)
Automate Your Wheel Strategy on DNLI
With Tiblio's Option Bot, you can configure your own wheel strategy including DNLI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DNLI
- Rev/Share 0.0
- Book/Share 6.5569
- PB 2.0192
- Debt/Equity 0.0433
- CurrentRatio 9.5632
- ROIC -0.4337
- MktCap 1923454240.0
- FreeCF/Share -2.2449
- PFCF -5.004
- PE -4.994
- Debt/Assets 0.0383
- DivYield 0
- ROE -0.359
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DNLI | Cantor Fitzgerald | Neutral | Overweight | -- | -- | April 10, 2025 |
| Resumed | DNLI | Morgan Stanley | -- | Overweight | $41 | $33 | March 7, 2025 |
| Initiation | DNLI | Deutsche Bank | -- | Buy | -- | $31 | Feb. 11, 2025 |
| Initiation | DNLI | Robert W. Baird | -- | Outperform | -- | $31 | Jan. 7, 2025 |
| Initiation | DNLI | William Blair | -- | Outperform | -- | -- | Jan. 3, 2025 |
| Upgrade | DNLI | Stifel | Hold | Buy | -- | $37 | Dec. 16, 2024 |
| Resumed | DNLI | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
| Downgrade | DNLI | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Oct. 7, 2024 |
News
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA?
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
Read More
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson's Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact.
Read More
Why You Shouldn't Bet Against Denali (DNLI) Stock
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Read More
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Read More
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.
Read More
About Denali Therapeutics Inc. (DNLI)
- IPO Date 2017-12-08
- Website https://www.denalitherapeutics.com
- Industry Biotechnology
- CEO Dr. Ryan J. Watts Ph.D.
- Employees 443